Melissa Pham

Abstract In this phase II trial, patients with endometrial cancer (EC) were randomized to everolimus/letrozole with (experimental arm) or without ribociclib (control arm) (ClinicalTrials.gov Identifier: NCT03008408). The primary endpoint was progression-free survival (PFS). Secondary endpoints included toxicity, overall survival (OS), objective response rate (ORR), and clinical benefit rate (CBR).

Highlights Poly(ADP-ribose) polymerase inhibitors (PARPi) are approved by the FDA as monotherapy for ovarian, breast, and pancreatic tumors harboring BRCA1/2 mutations, as well as castration-resistant prostate cancers with homologous recombination repair (HRR) mutations. Immune checkpoint blockade (ICB) – through the use of programmed cell death 1/programmed cell death ligand 1 (PD-1/PD-L1) inhibitors – has demonstrated durable responses in different solid tumors.

Brown J.S. et al. Targeting DNA repair in cancer: beyond PARP inhibitors. Cancer Discov. 2017; 7: 20-37 Luo J. et al. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell. 2009; 136: 823-837 Bartkova J. et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature. 2005; 434: 864-870 Gorgoulis V.G. et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature. 2005; 434: 907-913 Cerrato A. et al.